Researchers at NYU Abu Dhabi have developed a new class of smart molecules capable of both detecting and treating cancer, offering a more precise and potentially safer approach to cancer care.
The study, published in the Journal of the American Chemical Society, focuses on enhancing the capabilities of magnetic resonance imaging (MRI), a widely used diagnostic tool that enables doctors to visualise tumors inside the body. While MRI contrast agents typically assist only in diagnosis, the research team has successfully designed molecules that combine diagnostic imaging and therapeutic action within a single system.
Unique Molecular Design Enhances Performance
Unlike conventional drugs, which are usually small and structurally simple, these newly developed molecules feature interlocked structures resembling knots and rings.
This unique architecture enables the molecules to behave differently within biological environments, thereby improving both imaging accuracy and therapeutic effectiveness. The innovative design allows the molecules to perform multiple functions simultaneously, which represents a significant advancement in cancer treatment strategies.
Tumor-Activated Mechanism for Targeted Action
The molecules consist of manganese combined with organic components. Importantly, they remain inactive in healthy tissues, thereby reducing the risk of unintended damage.
However, once they enter the tumor microenvironment—where conditions are slightly more acidic—the molecules become activated. At this stage, they release manganese ions, which enhance MRI contrast while simultaneously triggering a therapeutic effect that damages cancer cells.
The research scientist Thirumurugan Prakasam, working in the Trabolsi research group at NYU Abu Dhabi, successfully synthesized these advanced molecular structures.
Ability to Cross the Blood–Brain Barrier
A key breakthrough in the study is the molecules’ ability to cross the blood–brain barrier, a major obstacle in the treatment and imaging of brain tumors.
The researchers demonstrated that these molecules can accumulate in glioblastoma tumors, enabling clear imaging of brain tumors, which are often difficult to detect and monitor using conventional MRI contrast agents.
Promising Results in Aggressive Brain Tumor Models
As reported by medicalxpress, the research team tested the technology in glioblastoma, one of the most aggressive and difficult-to-treat forms of brain cancer. The molecules successfully produced high-quality imaging while also exerting a therapeutic effect, demonstrating the potential of this dual-function approach.
According to Farah Benyettou, the lead researcher, the primary objective was to develop materials that allow physicians to visualise tumors clearly while simultaneously delivering targeted treatment. She emphasised that the ability to precisely image and treat brain tumors represents a particularly promising advancement.
Safer Alternative to Conventional MRI Contrast Agents
In addition to their therapeutic capabilities, the manganese-based compounds may offer a safer alternative to gadolinium, a metal commonly used in conventional MRI contrast agents. Gadolinium can accumulate in the body and may cause side effects in certain patients.
Therefore, the newly developed compounds could reduce safety concerns while improving diagnostic efficiency.
Towards Integrated Cancer Diagnosis and Treatment
Commenting on the significance of the research, Professor Ali Trabolsi, Professor of Chemistry at NYU Abu Dhabi, noted that the work brings diagnosis and treatment closer together. He highlighted that the unique molecular architecture provides capabilities that traditional drugs cannot achieve.
Overall, the findings introduce a new generation of MRI agents that integrate diagnosis and therapy into a single platform. This approach has the potential to make cancer care faster, safer, and more precise, paving the way for future clinical applications.